213 related articles for article (PubMed ID: 27484962)
1. Fractalkine/CX3CL1 in rheumatoid arthritis.
Nanki T; Imai T; Kawai S
Mod Rheumatol; 2017 May; 27(3):392-397. PubMed ID: 27484962
[TBL] [Abstract][Full Text] [Related]
2. Recruitment of CD16+ monocytes into synovial tissues is mediated by fractalkine and CX3CR1 in rheumatoid arthritis patients.
Yano R; Yamamura M; Sunahori K; Takasugi K; Yamana J; Kawashima M; Makino H
Acta Med Okayama; 2007 Apr; 61(2):89-98. PubMed ID: 17471309
[TBL] [Abstract][Full Text] [Related]
3. [Fractalkine--a proinflammatory chemokine in rheumatoid arthritis].
Blaschke S; Müller GA
Z Rheumatol; 2008 Sep; 67(5):424-8. PubMed ID: 18633630
[TBL] [Abstract][Full Text] [Related]
4. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis.
Ruth JH; Volin MV; Haines GK; Woodruff DC; Katschke KJ; Woods JM; Park CC; Morel JC; Koch AE
Arthritis Rheum; 2001 Jul; 44(7):1568-81. PubMed ID: 11465708
[TBL] [Abstract][Full Text] [Related]
5. Proinflammatory role of fractalkine (CX3CL1) in rheumatoid arthritis.
Blaschke S; Koziolek M; Schwarz A; Benöhr P; Middel P; Schwarz G; Hummel KM; Müller GA
J Rheumatol; 2003 Sep; 30(9):1918-27. PubMed ID: 12966591
[TBL] [Abstract][Full Text] [Related]
6. Fractalkine in rheumatoid arthritis and allied conditions.
Umehara H; Tanaka M; Sawaki T; Jin ZX; Huang CR; Dong L; Kawanami T; Karasawa H; Masaki Y; Fukushima T; Hirose Y; Okazaki T
Mod Rheumatol; 2006; 16(3):124-30. PubMed ID: 16767549
[TBL] [Abstract][Full Text] [Related]
7. Monocytes in rheumatoid arthritis: Circulating precursors of macrophages and osteoclasts and, their heterogeneity and plasticity role in RA pathogenesis.
Rana AK; Li Y; Dang Q; Yang F
Int Immunopharmacol; 2018 Dec; 65():348-359. PubMed ID: 30366278
[TBL] [Abstract][Full Text] [Related]
8. Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis.
Nanki T; Imai T; Nagasaka K; Urasaki Y; Nonomura Y; Taniguchi K; Hayashida K; Hasegawa J; Yoshie O; Miyasaka N
Arthritis Rheum; 2002 Nov; 46(11):2878-83. PubMed ID: 12428227
[TBL] [Abstract][Full Text] [Related]
9. T cell costimulation by fractalkine-expressing synoviocytes in rheumatoid arthritis.
Sawai H; Park YW; Roberson J; Imai T; Goronzy JJ; Weyand CM
Arthritis Rheum; 2005 May; 52(5):1392-401. PubMed ID: 15880821
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of fractalkine ameliorates murine collagen-induced arthritis.
Nanki T; Urasaki Y; Imai T; Nishimura M; Muramoto K; Kubota T; Miyasaka N
J Immunol; 2004 Dec; 173(11):7010-6. PubMed ID: 15557198
[TBL] [Abstract][Full Text] [Related]
11. Rationale for and clinical development of anti-fractalkine antibody in rheumatic diseases.
Muraoka S; Nishio J; Kuboi Y; Imai T; Nanki T
Expert Opin Biol Ther; 2020 Nov; 20(11):1309-1319. PubMed ID: 32401060
[No Abstract] [Full Text] [Related]
12. CX3CL1/fractalkine regulates the differentiation of human peripheral blood monocytes and monocyte-derived dendritic cells into osteoclasts.
Muraoka S; Kaneko K; Motomura K; Nishio J; Nanki T
Cytokine; 2021 Oct; 146():155652. PubMed ID: 34325117
[TBL] [Abstract][Full Text] [Related]
13. Fractalkine induces angiogenic potential in CX3CR1-expressing monocytes.
Park Y; Lee J; Kwak JY; Noh K; Yim E; Kim HK; Kim YJ; Broxmeyer HE; Kim JA
J Leukoc Biol; 2018 Jan; 103(1):53-66. PubMed ID: 28978662
[TBL] [Abstract][Full Text] [Related]
14. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets.
Schulz C; Schäfer A; Stolla M; Kerstan S; Lorenz M; von Brühl ML; Schiemann M; Bauersachs J; Gloe T; Busch DH; Gawaz M; Massberg S
Circulation; 2007 Aug; 116(7):764-73. PubMed ID: 17679613
[TBL] [Abstract][Full Text] [Related]
15. Fractalkine in vascular biology: from basic research to clinical disease.
Umehara H; Bloom ET; Okazaki T; Nagano Y; Yoshie O; Imai T
Arterioscler Thromb Vasc Biol; 2004 Jan; 24(1):34-40. PubMed ID: 12969992
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic intervention of inflammatory/immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway.
Imai T; Yasuda N
Inflamm Regen; 2016; 36():9. PubMed ID: 29259682
[TBL] [Abstract][Full Text] [Related]
17. Regulation of CX3CL1/fractalkine expression in endothelial cells.
Imaizumi T; Yoshida H; Satoh K
J Atheroscler Thromb; 2004; 11(1):15-21. PubMed ID: 15067194
[TBL] [Abstract][Full Text] [Related]
18. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1).
Lucas AD; Bursill C; Guzik TJ; Sadowski J; Channon KM; Greaves DR
Circulation; 2003 Nov; 108(20):2498-504. PubMed ID: 14581400
[TBL] [Abstract][Full Text] [Related]
19. The chemokine CX3CL1 (fractalkine) and its receptor CX3CR1: occurrence and potential role in osteoarthritis.
Wojdasiewicz P; Poniatowski LA; Kotela A; Deszczyński J; Kotela I; Szukiewicz D
Arch Immunol Ther Exp (Warsz); 2014 Oct; 62(5):395-403. PubMed ID: 24556958
[TBL] [Abstract][Full Text] [Related]
20. Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway.
Chandrasekar B; Mummidi S; Perla RP; Bysani S; Dulin NO; Liu F; Melby PC
Biochem J; 2003 Jul; 373(Pt 2):547-58. PubMed ID: 12729461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
